James, ND and Sydes, MR and Clarke, NW and Mason, MD and Dearnaley, DP and Spears, MR and Ritchie, AWS and Parker, CC and Russell, JM and Attard, G and De Bono, J and Cross, W and Jones, RJ and Thalmann, G and Amos, C and Matheson, D and Millman, R and Alzouebi, M and Beesley, S and Birtle, AJ and Brock, S and Cathomas, R and Chakraborti, P and Chowdhury, S and Cook, A and Elliott, T and Gale, J and Gibbs, S and Graham, JD and Hetherington, J and Hughes, R and Laing, R and McKinna, F and McLaren, DB and O'Sullivan, JM and Parikh, O and Peedell, C and Protheroe, A and Robinson, AJ and Srihari, N and Srinivasan, R and Staffurth, J and Sundar, S and Tolan, S and Tsang, D and Wagstaff, J and Parmar, MKB
(2015)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
The Lancet, 387 (10024).
1163 - 1177.
ISSN 0140-6736
DOI: https://doi.org/10.1016/S0140-6736(15)01037-5
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)